Freedom Meditech Receives JumpStart ...(in the field.The results of initial stud...),Health

JumpStart Entrepreneur-in-Residence Kevin Mendelsohn, who will be working with Freedom Meditech, has great expectations for the company. "While there are many companies competing to develop a non-invasive blood glucose monitor, the current standard is still the finger prick method, which has obvious user compliance and convenience drawbacks that lead to poor disease management," Mendelsohn said. "Freedom Meditech's technology has the promise to solve a critical unmet medical need and improve the standard of living for millions of patients throughout the world."

Freedom Meditech's Chief Executive Officer, Craig Misrach began developing the business plan for the company while he was a graduate student at the Darden School of Business at the University of Virginia.

"JumpStart's extensive life science investment portfolio, early-stage business development support, and industry and capital connections were all key factors in our decision to welcome them to our current investor base," said Misrach. "JumpStart also provides an excellent financing complement to our extensive list of Ohio-based operational collaborators."

Freedom Meditech maintains business and research and development relationships with The University of Toledo, Battelle, MAGNET, researchers at the Cole Eye Institute at the Cleveland Clinic, BioEnterprise, LNE Group, BioOhio, and several other medical device commercialization experts across the country.

This is JumpStart's 43rd investment in its 32nd company. Other healthcare companies in JumpStart's portfolio include AcelleRx Therapeutics, AnalizaDx, CardioInsight Technologies, CerviLenz, Inc., Great Lakes Pharmaceuticals, Synapse Biomedical and Telerad Express.

About Freedom Meditech,
'/>"/>